Evidence map›Paper›PMID 41174496›Full record

ArticleMolecular medicine (Cambridge, Mass.)2025

From Bench to Clinic: The 2024 FASEB Scientific Research Conference on NAD Metabolism and Signaling.

Shin-Ichiro Imai, Eija Pirinen, Michael N Sack, Jonas T Treebak, Charalampos Tzoulis, Santina Bruzzone, Andreas H Guse, Michael O Hottiger, Xiaolu A Cambronne

Abstract readConference Proceedings
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular medicine (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shin-Ichiro Imai *Washington University School of Medicine, St. Louis, MO, USA.
Eija Pirinen *Research Unit of Biomedicine and Internal Medicine, Faculty of Medicine, University of Oulu, Oulu, Finland.
Michael N Sack *National Heart, Lung and Blood Institute, NHLBI, NIH, Bethesda, MD, USA.
Jonas T Treebak *Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Charalampos Tzoulis *Department of Neurology, Neuro-SysMed, Haukeland University Hospital, Jonas Lies vei 65, Bergen, 5021, Norway.
Santina Bruzzone *University of Genova, Genova, Italy.
Andreas H Guse *Department of Biochemistry and Molecular Cell Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Michael O Hottiger *Department of Molecular Mechanisms of Disease, University of Zurich, Zurich, Switzerland.
Xiaolu A CambronneDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, 78737, USA. lulu@austin.utexas.edu.

Funding

NAD Metabolism and SignalingR13AG089927 · NIA · FEDERATION OF AMER SOC FOR EXPER BIOLOGY · PI CAMBRONNE, XIAOLU ANG · 2024 to 2024
$45k
NIA NIH HHS R13 AG089927
6 · The paper itself

Abstract

The 2024 FASEB Scientific Research Conference on NAD Metabolism and Signaling was held in Lisbon, Portugal and served to (1) unite researchers, clinicians, and trainees, (2) create opportunities for early-stage investigators by showcasing their work on an international stage and promote collaborations, (3) train the next generation of scientists in the field, and (4) improve human health by furthering our understanding of NAD

Indexed as

NADSignal TransductionAnimalsHumansMetabolic Networks and PathwaysNAD

Identifiers

PMID41174496
PMCPMC12579426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.